May 15, 2017 20:08 pm UTC| Business
SaaS License Revenue Increases 8.1% in the Second Quarter of Fiscal 2017 Gross Margin Improves to 57% in the Second Quarter of Fiscal 2017 Company Generates Positive Adjusted EBITDA for the Second Consecutive Quarter of...
May 15, 2017 20:08 pm UTC| Business
SaaS License Revenue Increases 8.1% in the Second Quarter of Fiscal 2017 Gross Margin Improves to 57% in the Second Quarter of Fiscal 2017 Company Generates Positive Adjusted EBITDA for the Second Consecutive Quarter of...
May 15, 2017 20:08 pm UTC| Business
SaaS License Revenue Increases 8.1% in the Second Quarter of Fiscal 2017 Gross Margin Improves to 57% in the Second Quarter of Fiscal 2017 Company Generates Positive Adjusted EBITDA for the Second Consecutive Quarter of...
Mustang Bio Reports First Quarter 2017 Financial Results and Recent Corporate Highlights
May 15, 2017 20:08 pm UTC| Business
NEW YORK, May 15, 2017 -- Mustang Bio, Inc. (“Mustang”), a Fortress Biotech (NASDAQ:FBIO) Company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR...
Mustang Bio Reports First Quarter 2017 Financial Results and Recent Corporate Highlights
May 15, 2017 20:08 pm UTC| Business
NEW YORK, May 15, 2017 -- Mustang Bio, Inc. (“Mustang”), a Fortress Biotech (NASDAQ:FBIO) Company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR...
Mustang Bio Reports First Quarter 2017 Financial Results and Recent Corporate Highlights
May 15, 2017 20:08 pm UTC| Business
NEW YORK, May 15, 2017 -- Mustang Bio, Inc. (“Mustang”), a Fortress Biotech (NASDAQ:FBIO) Company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR...
Mustang Bio Reports First Quarter 2017 Financial Results and Recent Corporate Highlights
May 15, 2017 20:08 pm UTC| Business
NEW YORK, May 15, 2017 -- Mustang Bio, Inc. (“Mustang”), a Fortress Biotech (NASDAQ:FBIO) Company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR...
Mother of All Deals: India & EU Seal Historic FTA After 20 Years